The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor agonist liraglutide.

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could be used for in adults and children 10 and up. The new drug, sold under the name Victoza and made by Hikma Pharmaceuticals USA Inc., follows the approval of the generic GLP-1 exanatide last month, sold under the name Byetta.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide injection, which is currently in shortage and sold under the brand name Victoza,

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug Administration. Compounded copycat drugs containing tirzepatide, many sold by online pharmacies, will no longer be allowed.